Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study

Shukui Qin, Shanzhi Gu, Stephen L. Chan, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Li Xu, Xianglin Yuan, Da Li, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Jinghua Du, Wei Shi, Ann‐Lii Cheng, Ahmed O. Kaseb, Arndt Vogel